Abstract:Abstract Cancer responses to drug treatment are highly heterogeneous. We postulate that spatial determinants in the tumour play a critical role in cancer therapy outcomes. Here, we will present two spatial transcriptomics studies on spatial responses to immunotherapy and chemotherapy. Immune checkpoint inhibitors (ICI) are used to treat recurrent metastatic oropharyngeal squamous cell carcinomas (OPSCC). Unfortunately, less than 30% of patients benefit from this therapy. Thus, we performed spatial transcriptomics (ST) and in-situ multiprotein detection (PhenoCycler-Fusion) on tissue isolated from a patient diagnosed with metastatic OPSCC. The patient’s primary oral tumour responded to chemo-radio therapy, followed by nivolumab ICI. However, new soft pallet OPSCCs resurged. Subsequent pembrolizumab combined with lenvatinib (VEGFR inhibitor) treatment had an initial effect, butnew recurrent oral tumours re-emerged suggesting drug resistance. Using ST, we observed high expression of drug resistance genes such as SNAI2, SOX4 and NDRG1 consistent with the disease aggressive behaviour. Although, PD-1/PD-L1 expression was not observed, we identified 13 over-expressed druggable targets (i.e., EGFR, TF, VEGF) and >10 experimental targets. To rank each drug’s potential success, we measured the co-expression of each target ligand-receptor pair (L/R), reducing the candidates to 4 pathways (TF/TFRC> VEGFA/NRP1> PGF/NRP1> TGFB1/VASN>VEGFA/GPC1). Furthermore, TF/TFRC and VEGFA/NRP1 expected downstream genes were differentially over-expressed where positive LR signal was detected. Similarly, we used ST to define the cellular diversity within a sonic hedgehog (SHH) patient-derived model of Medulloblastoma (MB) and identified how cells specific to a transcriptional state or spatial location are pivotal in responses to treatment with the CDK4/6 inhibitor, Palbociclib. We distinguished neoplastic and non-neoplastic cells within tumours and from the surrounding cerebellar tissue, further refining pathological annotation. We identified a regional response to Palbociclib, with reduced proliferation and induced neuronal differentiation in both treated tumours. Additionally, we resolved at cellular resolution a distinct tumour “interface” where the tumour cells contacted neighbouring mouse brain tissue, consisting of abundant astrocytes and microglia, and continued to proliferate despite Palbociclib treatment. Our data highlight the power of a spatial multi-omics approach to characterise the response of a tumour to targeted therapy and provide further insights into the molecular and cellular basis underlying the response and resistance to cancer therapies. Citation Format: Xiao Tan, Andrew Causer, Tuan Quang Anh Vo, Ning Ma, Bassem Ben Cheikh, Laura Genovesi, Jazmina Gonzalez-Cruz, Quan Nguyen, Oliver Braubach. Applying spatial omics and computational integrative analyses to study drug responses and cancer immune cell interactions. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 4703.

Spatial omics techniques and data analysis for cancer immunotherapy applications

Spatial omics: Navigating to the golden era of cancer research

The promise and challenge of spatial omics in dissecting tumour microenvironment and the role of AI

A review of spatial profiling technologies for characterizing the tumor microenvironment in immuno-oncology.

Computational methods and biomarker discovery strategies for spatial proteomics: a review in immuno-oncology

Spatial omics technologies for understanding molecular status associated with cancer progression

Applicability of Spatial Technology in Cancer Research

Progress in research on tumor microenvironment-based spatial omics technologies

Advances in spatial multi-omics in tumors

Spatial analyses of immune cell infiltration in cancer: current methods and future directions: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer

Mapping cancer biology in space: applications and perspectives on spatial omics for oncology

Clinical Implications of Basic Research: Exploring the Transformative Potential of Spatial 'Omics in Uro-oncology

Spatial transcriptomics and proteomics technologies for deconvoluting the tumor microenvironment

Spatiotemporal metabolomic approaches to the cancer-immunity panorama: a methodological perspective

Abstract 4703: Applying spatial omics and computational integrative analyses to study drug responses and cancer immune cell interactions

Spatial landscapes of cancers: insights and opportunities

Abstract 2125: Towards a spatial view of immune cell function in cancer

Historical perspective and future directions: computational science in immuno-oncology

Single-Cell Informatics for Tumor Microenvironment and Immunotherapy

Spatial oncology: Translating contextual biology to the clinic

Spatial dissection of the immune landscape of solid tumors to advance precision medicine